机译:Bendamustine随后是慢性淋巴细胞白血病(CLL2袋)中的Obinutuzumab和Venetoclax:Multicentre,开放标签,第2期试验的主要终点分析
Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn German CLL Study;
Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn German CLL Study;
Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn German CLL Study;
Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn German CLL Study;
Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn German CLL Study;
Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn German CLL Study;
Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn German CLL Study;
Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn German CLL Study;
Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn German CLL Study;
Department III of Internal Medicine University Hospital Ulm;
Department III of Internal Medicine University Hospital Munich Ludwig-Maximilians-University;
Gesundheitszentrum St Marien;
Stauferklinikum Schw?bisch-Gmünd;
Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn German CLL Study;
Department III of Internal Medicine University Hospital Rostock;
Department of Internal Medicine II Campus Kiel University of Schleswig-Holstein;
Department of Internal Medicine II Campus Kiel University of Schleswig-Holstein;
Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn German CLL Study;
Department III of Internal Medicine University Hospital Ulm;
Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn German CLL Study;
Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn German CLL Study;
机译:Bendamustine随后是慢性淋巴细胞白血病(CLL2袋)中的Obinutuzumab和Venetoclax:Multicentre,开放标签,第2期试验的主要终点分析
机译:Ibrutinib Plus obinutuzumab与氯苯脲加上obInutuzumab在一线治疗慢性淋巴细胞白血病(照明):多期,随机,开放标签,第3阶段试验
机译:耐钙淋巴细胞白血病的威尼斯洛克斯在伊布洛尼布后进展:临时分析多期,开放标签,第2期试验
机译:第3期临床试验的回顾性分析,评价患有慢性肾病的贫血药物B的疗效
机译:Bendamustine然后是慢性淋巴细胞白血病中的ofatumumab和伊布勒替尼:多中心的主要终点分析开放标签II期试验(CLL2-BIO)
机译:Bendamustine(b),其次是慢性淋巴细胞白血病(CLL)患者的Obinutuzumab(g)和venetoclax(a):德国Cll研究组的Cll2-bag试验(Gcllsg)